Literature DB >> 22733914

Fluoroscopically guided dilation of esophageal strictures in patients with dystrophic epidermolysis bullosa: long-term results.

Stavros Spiliopoulos1, Tarun Sabharwal, Miltiadis Krokidis, Panagiotis Gkoutzios, Jemima Mellerio, Renato Dourado, Andreas Adam.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the immediate and long-term outcomes after fluoroscopically guided balloon dilation of esophageal strictures in a series of patients with dystrophic epidermolysis bullosa (DEB).
MATERIALS AND METHODS: Between 2005 and 2011, the medical records of all patients with DEB treated with fluoroscopically guided balloon dilation of esophageal strictures were included in the study and retrospectively analyzed. The indication for treatment was dysphagia attributed to at least one radiologically verified esophageal stricture. The primary endpoints of the study included procedural technical success, clinical improvement assessed with a 0-4 dysphagia score, and major complication rate. Secondary endpoints were patient survival and reintervention rates.
RESULTS: Nineteen consecutively registered patients with DEB (age range, 10-51 years; mean, 30 ± 12.2 years) and dysphagia due to esophageal strictures were treated with fluoroscopically guided balloon dilation. In total, 90 procedures and 121 dilations were performed to manage 28 lesions. Balloon diameter ranged from 8 to 18 mm. The mean follow-up time was 47.51 ± 16.64 months (range, 17-73 months). The technical success rate was 96.7% (87/90). There were no major complications. The mean reintervention rate was 1.19 dilations per patient per year, and the postprocedural dysphagia score (0.72 [95% CI, 0.56-0.87]) was significantly lower than baseline (2.50 [95% CI 2.35-2.65]) (p < 0.001).
CONCLUSION: Repeated fluoroscopically guided balloon dilation is safe and effective for the management of dysphagia caused by esophageal strictures in DEB. Use of this technique was associated with marked clinical improvement in dysphagia and satisfactory long-term reintervention rates with no major complications.

Entities:  

Mesh:

Year:  2012        PMID: 22733914     DOI: 10.2214/AJR.11.8159

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Stavros Spiliopoulos; Nikolaos Davanos
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Endoscopic management of esophageal stenosis in children: New and traditional treatments.

Authors:  Luigi Dall'Oglio; Tamara Caldaro; Francesca Foschia; Simona Faraci; Giovanni Federici di Abriola; Francesca Rea; Erminia Romeo; Filippo Torroni; Giulia Angelino; Paola De Angelis
Journal:  World J Gastrointest Endosc       Date:  2016-02-25

3.  Oral viscous budesonide as a first-line approach to esophageal stenosis in epidermolysis bullosa: an open-label trial in six children.

Authors:  Andrea Zanini; Sophie Guez; Simona Salera; Giorgio Farris; Anna Morandi; Valerio Gentilino; Ernesto Leva; Francesca Manzoni; Maria Angela Pavesi; Susanna Esposito; Francesco Macchini
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

Review 4.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.